Compare ResMed Inc. (RMD) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Travere Therapeutics Inc. Common Stock — how do they compare? ResMed Inc. trades at $240.35 (market cap $33.09B), while Travere Therapeutics Inc. Common Stock trades at $54.62 (market cap $5.02B). The key difference: ResMed Inc. is far larger — about 6.6× Travere Therapeutics Inc. Common Stock's market cap, and ResMed Inc. pays a 1.12% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| RMD | TVTX | |
|---|---|---|
Market Cap | $33.09B | $5.02B |
Volume | 1,019,685 | 2,060,842 |
Sector | Health | Health |
52-Week High | $275.96 | $67.52 |
52-Week Low | $182.82 | $26.79 |
Typical Hold Time | 51 Days | 0 Days |
Enterprise Value | $32.45B | $5.15B |
Dividend Yield | 1.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $240.56, up 2.35% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 2025 revenue of $5.15B, net income of $1.40B (27.21% margin), and consistent earnings beats. Recent news highlights management's participation in healthcare conferences and upcoming Q1 2027 earnings on October 29, 2026.
Outlook remains positive with 12-14% EPS growth guidance and analyst consensus target of $243.56. Key risks include competitive pressures and ongoing legal investigations. Institutional ownership trends show continued accumulation by major funds, supporting the bullish sentiment.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
